Improving Oral Delivery of Cytarabine for Leukemia Treatment
Author Information
Author(s): Said Abdelrahman R., Arafa Mona F., El-Dakroury Walaa A., Alshehri Sultan, El Maghraby Gamal M.
Primary Institution: King Saud University
Hypothesis
Can niosomes and bilosomes enhance the intestinal absorption and efficacy of cytarabine in treating acute myeloid leukemia?
Conclusion
Niosomes and bilosomes significantly improved the intestinal absorption and anti-leukemic effects of cytarabine compared to the drug solution.
Supporting Evidence
- Cytarabine-loaded niosomes and bilosomes showed improved intestinal absorption parameters.
- Both formulations significantly reduced white blood cell counts in leukemia-induced rats.
- Niosomes and bilosomes enhanced the anti-leukemic effect of cytarabine compared to the drug solution.
- Pathological examination revealed decreased blast cells in peripheral blood after treatment with niosomal and bilosomal formulations.
Takeaway
This study shows that special tiny bubbles called niosomes and bilosomes can help a medicine called cytarabine work better in treating leukemia by helping it get absorbed in the body more effectively.
Methodology
The study used niosomes and bilosomes to encapsulate cytarabine and evaluated their effects on intestinal absorption using an in situ rabbit model and assessed anti-leukemic effects in a rat model.
Limitations
The study did not include a control group for drug-free niosomes and bilosomes to assess the effect of formulation components.
Participant Demographics
Male albino rats weighing 110 to 130 g were used for the in vivo study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website